       Document 0360
 DOCN  M9620360
 TI    Improved vaccination response during ranitidine treatment, and increased
       plasma histamine concentrations, in patients with B cell chronic
       lymphocytic leukemia.
 DT    9602
 AU    Jurlander J; de Nully Brown P; Skov PS; Henrichsen J; Heron I; Obel N;
       Mortensen BT; Hansen MM; Geisler CH; Nielsen HJ; Department of
       Hematology, University Hospital Rigshospitalet,; Copenhagen, Denmark.
 SO    Leukemia. 1995 Nov;9(11):1902-9. Unique Identifier : AIDSLINE
       MED/96071143
 AB    Patients with B cell chronic lymphocytic leukemia (B-CLL) have decreased
       capacity to mount relevant antibody responses upon immunization, and
       development of hypogammaglobulinemia is part of the natural history of
       the disease. We investigated the influence of histamine type-2 (H2)
       receptor blockade by ranitidine on the in vivo antibody production in
       B-CLL patients following vaccination. Anti-polysaccharide antibodies in
       B-CLL patients, vaccinated with a tetanus-toxoid conjugated vaccine
       against Haemophilus influenzae type-B (Hib), reached long-term
       protective levels in more than 90% of B-CLL patients randomized to
       ranitidine treatment, as compared to 43% of the untreated patients (P =
       0.024). No difference in the response to vaccination against influenza
       virus types A and B protein could be detected between the two groups.
       Plasma histamine levels were 2-fold to 20-fold higher in 23 out of 31
       B-CLL patients, compared to normal controls, and these levels showed a
       significant positive correlation to disease duration. These findings
       indicate the possibility of improving in vivo antibody production
       against a highly relevant pathogen in B-CLL patients by histamine type-2
       receptor blockade, and the combined finding of an immune-stimulatory
       effect of ranitidine and increased plasma histamine levels, strongly
       suggests the involvement of histamine in the pathogenesis of B-CLL
       immunodeficiency.
 DE    Adjuvants, Immunologic/*THERAPEUTIC USE  Adult  Aged  Antibodies,
       Bacterial/BIOSYNTHESIS  Cells, Cultured  Female  Granulocyte-Macrophage
       Colony-Stimulating Factor/BLOOD  Haemophilus Vaccines/*IMMUNOLOGY
       Histamine/*BLOOD  Histamine H2 Antagonists/*THERAPEUTIC USE  Human
       Interleukin-3/BLOOD  Leukemia, B-Cell, Chronic/IMMUNOLOGY/*THERAPY
       Lymphocyte Transformation/DRUG EFFECTS  Male  Middle Age
       Ranitidine/*THERAPEUTIC USE  Receptors, IgE/METABOLISM  Support,
       Non-U.S. Gov't  Vaccination  CLINICAL TRIAL  JOURNAL ARTICLE  RANDOMIZED
       CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

